Understanding the DILI Risks of Antisense Oligonucleotides and the Value of Predictive In Vitro Testing
Antisense oligonucleotides (ASOs) offer therapeutic avenues for diseases that are currently unmet by alternative therapeutic modalities. However, the development of therapeutic ASOs is often hampered by hepatotoxicity. In this blog, we explore why 3D human liver microtissues are becoming an indispensable tool for de-risking ASO drug candidates and for reducing attrition in late-stage drug development.Â